Abstract：
:Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, weight loss, and fatigue. Symptoms are driven by an overall hypercytokinemia, predominantly IL-6. While under clinical development, siltuximab was studied in several other disease states including multiple myeloma, non-Hodgkin lymphomas, and several solid tumors in which it did not demonstrate significant benefit. The efficacy of siltuximab in MCD is mainly confined to systemic symptomatic response and quality of life benefits with minimal complete responses and approximately 30 % partial responses, by radiographic criteria. Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical development and pharmaceutical approval of siltuximab.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Davis CC,Shah KS,Lechowicz MJdoi
10.1007/s11912-015-0453-1subject
Has Abstractpub_date
2015-07-01 00:00:00pages
29issue
7eissn
1523-3790issn
1534-6269journal_volume
17pub_type
杂志文章,评审abstract：:Primary and metastatic spinal mesenchymal tumors are uncommon lesions. Surgical management of these tumors remains a challenge. En bloc wide resection provides the best chance for local tumor control and long-term survival. However, limitations to this technique include technical considerations (including neurovascula...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0036-2
更新日期：2006-07-01 00:00:00
abstract：:Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vinc...
journal_title：Current oncology reports
pub_type： 杂志文章
doi：10.1007/s11912-012-0281-5
更新日期：2013-02-01 00:00:00
abstract：:The prodrug strategy has its own particular real and theoretic obstacles. Clinical strategies and research efforts have tried to approach these problems. The bystander effect, whereby nontransduced cells are affected by simple proximity to those that have received the novel gene, has enabled many prodrug systems to be...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0006-z
更新日期：2000-01-01 00:00:00
abstract：:Results of treatment for patients with non-Hodgkin's lymphomas have significantly improved over the last decade, especially following the discovery that anti-CD20 antibody therapy can significantly change the outlook for patients with both aggressive and indolent lymphomas. Although investigators have previously attem...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0128-x
更新日期：2010-11-01 00:00:00
abstract：:Aflibercept (known as ziv-aflibercept in the USA and sold under the trade name Zaltrap®) is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factors A and B and placental growth factor. Its unique mechanism of action with respect to o...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0368-7
更新日期：2014-02-01 00:00:00
abstract：PURPOSE OF REVIEW:Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS:With the rise of novel therapeutic techniques and med...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-019-0856-5
更新日期：2019-11-14 00:00:00
abstract：:The topoisomerase I inhibitors such as irinotecan and topotecan are active agents against small-cell lung cancer that are effective in treating not only chemotherapy-naïve tumors but also progressed-stage tumors after treatment with cisplatin-based regimens, because their mechanism of antitumor activity differs from t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0018-3
更新日期：2001-03-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. We focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies and future strategies. RECENT FINDINGS:The number of PD-1/PD-L1...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00928-5
更新日期：2020-06-12 00:00:00
abstract：PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0694-x
更新日期：2018-04-11 00:00:00
abstract：:Cancer risk has become a significant research topic due to an increase in statistical risk models built to predict cancer incidence or mortality. Over the past 3 years, 15 models on the development of different types of cancer, including breast, colorectal, prostate, gastric, lung, ovarian, pancreatic, testicular, and...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-007-0071-7
更新日期：2007-11-01 00:00:00
abstract：:For a variety of medical conditions and procedures, a higher volume-better outcome relationship has been hypothesized for over 25 years. An extensive, consistent body of literature supports a relationship between hospital volume and short-term outcomes for cancers treated with technologically complex surgical procedur...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0026-3
更新日期：2001-09-01 00:00:00
abstract：:Following resection of hepatic colorectal metastases, there are few criteria for predicting which patients have more aggressive disease and are, therefore, more likely to experience recurrence and reduced survival. Traditionally, primary tumor stage, preoperative carcinoembryonic antigen level, time from primary tumor...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-007-0021-4
更新日期：2007-05-01 00:00:00
abstract：:Neuroblastoma is the most common extracranial tumor of childhood, with about 650 new cases each year in the United States. The clinical course of neuroblastoma is variable and depends on age at diagnosis, staging, histology, and specific genetic abnormalities, such as MYCN oncogene amplification or aberrations of chro...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0059-6
更新日期：2009-11-01 00:00:00
abstract：:Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0048-9
更新日期：2009-09-01 00:00:00
abstract：:Patients with head and neck cancers are excellent candidates for gene therapy. With few effective alternatives for patients with recurrent or locally metastatic disease, gene therapy offers a new approach for local control and the possibility to enhance other treatment modalities as well. Different therapeutic genes, ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-999-0024-4
更新日期：1999-01-01 00:00:00
abstract：:Chordomas and chondrosarcomas of the skull base are rare, indolent tumors with a natural history of locally invading their surroundings. Safe, maximal resection is the mainstay of treatment, followed by adjuvant radiation therapy. Even with multimodality therapy, local recurrence remains the most common failure patter...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0052-5
更新日期：2008-07-01 00:00:00
abstract：:Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin's lymphoma. PIOL typically presents as a vitritis that is unresponsive to corticosteroid t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0029-6
更新日期：2005-01-01 00:00:00
abstract：:Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This articl...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-003-0114-7
更新日期：2003-05-01 00:00:00
abstract：:Notch signaling plays crucial roles in many developmental pathways, with Notch mutations linked to several developmental disorders. Because many pediatric malignancies arise from dysregulated development, roles for Notch signaling in these cancers are to be expected. Evidence to support this is now emerging as the Not...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0071-2
更新日期：2008-11-01 00:00:00
abstract：:New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and pa...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0073-2
更新日期：2005-05-01 00:00:00
abstract：:Radiation plays an important role in the multimodal management of tumors of the gastrointestinal (GI) system. Intensity-modulated radiation therapy (IMRT) is a technological development that was introduced to limit the acute and late toxicities commonly associated with conventional radiation therapy. Numerous preclini...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0032-9
更新日期：2008-05-01 00:00:00
abstract：:Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide and has a poor overall survival across all stages of disease. The recent advancement of gene expression technology addresses the phenotypic complexity of many diseases, including NSCLC. These genomic approaches have shown great prom...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0037-z
更新日期：2009-07-01 00:00:00
abstract：PURPOSE OF REVIEW:Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0693-y
更新日期：2018-04-11 00:00:00
abstract：:Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/BF02951428
更新日期：2007-01-01 00:00:00
abstract：:The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-003-0012-z
更新日期：2003-11-01 00:00:00
abstract：:The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-012-0227-y
更新日期：2012-04-01 00:00:00
abstract：:Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0089-0
更新日期：2010-05-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS:In low-risk patients, RT could be omitted but, at ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0592-7
更新日期：2017-05-01 00:00:00
abstract：:The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical tr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-996-0008-6
更新日期：2004-01-01 00:00:00
abstract：:Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0075-z
更新日期：2000-05-01 00:00:00
